| | Identification | Back Directory |  | [Name] 
 PAC-14028
 |  | [CAS] 
 1005168-10-4
 |  | [Synonyms] 
 PAC-14028
 PAC14028; PAC 14028
 2-Propenamide, N-[(1R)-1-[3,5-difluoro-4-[(methylsulfonyl)amino]phenyl]ethyl]-3-[2-propyl-6-(trifluoromethyl)-3-pyridinyl]-, (2E)-
 |  | [Molecular Formula] 
 C21H22F5N3O3S
 |  | [MDL Number] 
 MFCD28502100
 |  | [MOL File] 
 1005168-10-4.mol
 |  | [Molecular Weight] 
 491.47
 | 
 | Chemical Properties | Back Directory |  | [density ] 
 1.381±0.06 g/cm3(Predicted)
 |  | [storage temp. ] 
 Store at -20°C
 |  | [solubility ] 
 DMSO: 50 mg/mL (101.74 mM)
 |  | [form ] 
 Solid
 |  | [pka] 
 7.41±0.10(Predicted)
 |  | [color ] 
 White to off-white
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 Asivatrep (PAC-14028) is a potent and selective transient receptor potential vanilloid type I (TRPV1) antagonist.
 |  | [in vivo] 
 
 Asivatrep (PAC-14028) shows a plasma half-life of 2.1 h in rats while it is extended slightly to 3.8 h in minipigs. Oral bioavailability at 10 mg/kg dose is determined to be 52.7% and 64.2% in rats and minipigs, respectively suggesting that Asivatrep (PAC-14028) is relatively well-absorbed through oral route[1]. Asivatrep (PAC-14028) could inhibit capsaicin-evoked calcium influx in keratinocytes at sub-micromolar concentrations. This potent TRPV1 antagonistic activity in keratinocytes is manifested in vivo as the blockade of capsaicin-induced blood perfusion increase, and the accelerated barrier recovery from tape-stripping-induced barrier damages in hairless mice[3]. |  | [References] 
 [1] Park YH, et al. Oral and topical pharmacokinetic studies of a novel TRPV1 antagonist, PAC-14028 in rats and minipigs using liquid chromatography/tandem mass spectrometric method. J Pharm Biomed Anal. 2012 Mar 5;61:8-14. DOI:10.1016/j.jpba.2011.11.011
 [2] Lim KM, et al. Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6. DOI:10.1007/s12272-012-0321-6
 [3] Yun JW, et al. TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery. J Dermatol Sci. 2011 Apr;62(1):8-15. DOI:10.1016/j.jdermsci.2010.10.014
 | 
 | 
                    
                        
                            | Company Name: | guoyungurui |  
                            | Tel: | 18162595016; 18162595016 |  
                            | Website: | https://www.chemicalbook.com/supplier/25521782/ |  |